Literature DB >> 7921615

Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental area.

B Bowery1, L A Rothwell, G R Seabrook.   

Abstract

1. Electrophysiological recordings were made from presumed dopaminergic neurons in the substantia nigra pars compacta and ventral tegmental area of rat brain slices. The ability of selective dopamine receptor agonists to hyperpolarize neurones and inhibit cell firing, as well as the ability of dopamine receptor antagonists to block responses to quinpirole were compared. 2. Six dopamine receptor agonists were examined for their ability to hyperpolarize neurones within the substantia nigra pars compacta. Of these, the most potent ligand tested was naxagolide with an EC50 value of 20 nM and estimated maximum of 10 mV. The rank order of agonist potency was naxagolide > quinpirole > apomorphine > dopamine. 3. Quinpirole was more potent at inhibiting cell firing in the substantia nigra pars compacta (pIC50 = 7.65 +/ 0.06, n = 35) than in the ventral tegmental area (pIC50 = 7.24 +/- 0.06, n = 32; P < 0.01, Student's t test). 7-Hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OH-DPAT), a putative D3 selective agonist, had a comparable potency to quinpirole in both the ventral tegmental area (pIC50 = 7.39 +/- 0.26, n = 4), and substantia nigra pars compacta (pIC50 = 7.71 +/- 0.20; n = 4). 4. The inhibition of cell firing by quinpirole was antagonized by haloperidol, S(-)-sulpiride, clozapine, and ritanserin. S(-)-sulpiride and haloperidol had the highest estimated affinities in the substantia nigra, with pA2 values of 8.97 (slope = 0.85) and 8.20 (slope = 2.09) respectively. The pA2 values for S(-)-sulpiride and haloperidol in the ventral tegmental area were 8.07 (slope = 0.87) and 8.11 (slope = 1.48)respectively. Clozapine had a lower functional affinity than S(-)-sulpiride and haloperidol in both the substantia nigra (pA2 = 6.47, slope = 1.19) and ventral tegmental area (pA2 = 6.53, slope 0.87). Ritanserin,a 5-HT2 receptor antagonist that also binds to D2.u. dopamine receptors, caused a slight but significant shift in the concentration-effect curve to quinpirole with an estimated pKA of 6.97 +/- 0.13(n =4) in the substantia nigra and pKA of 7.12 +/- 0.22 (n =4) in the ventral tegmental area.5. Comparison of these data with the binding affinity for cloned dopamine receptors demonstrates that the responses to quinpirole on dopaminergic neurones in both the A9 (substantia nigra) and A10(ventral tegmental area) brain areas are consistent with the activation of predominantly D2, and not D3 or D4 dopamine receptors. Furthermore, the similarity in functional affinity of antagonists for these receptors suggest that the mesolimbic selectivity of atypical neuroleptics, like clozapine, may be a consequence of their actions on other receptors or their effects elsewhere in the brain.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7921615      PMCID: PMC1910205          DOI: 10.1111/j.1476-5381.1994.tb13161.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

Review 1.  Drugs and receptors. An overview of the current state of knowledge.

Authors:  T Kenakin
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

2.  Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurones in the rat.

Authors:  T Skarsfeldt; J Perregaard
Journal:  Eur J Pharmacol       Date:  1990-07-17       Impact factor: 4.432

3.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.

Authors:  P Sokoloff; B Giros; M P Martres; M L Bouthenet; J C Schwartz
Journal:  Nature       Date:  1990-09-13       Impact factor: 49.962

4.  Cloning and expression of a rat D2 dopamine receptor cDNA.

Authors:  J R Bunzow; H H Van Tol; D K Grandy; P Albert; J Salon; M Christie; C A Machida; K A Neve; O Civelli
Journal:  Nature       Date:  1988 Dec 22-29       Impact factor: 49.962

5.  Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine.

Authors:  H H Van Tol; J R Bunzow; H C Guan; R K Sunahara; P Seeman; H B Niznik; O Civelli
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

6.  Actions of cocaine on rat dopaminergic neurones in vitro.

Authors:  M G Lacey; N B Mercuri; R A North
Journal:  Br J Pharmacol       Date:  1990-04       Impact factor: 8.739

7.  Irreversible receptor inactivation reveals differences in dopamine receptor reserve between A9 and A10 dopamine systems: an electrophysiological analysis.

Authors:  R F Cox; B L Waszczak
Journal:  Brain Res       Date:  1990-11-26       Impact factor: 3.252

8.  Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition.

Authors:  L Ugedo; J Grenhoff; T H Svensson
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 9.  Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview.

Authors:  J M Kane
Journal:  Br J Psychiatry Suppl       Date:  1992-05

10.  Electrophysiological characterization of potent agonists and antagonists at pre- and postsynaptic GABAB receptors on neurones in rat brain slices.

Authors:  G R Seabrook; W Howson; M G Lacey
Journal:  Br J Pharmacol       Date:  1990-12       Impact factor: 8.739

View more
  14 in total

1.  Activation of human D3 dopamine receptor inhibits P/Q-type calcium channels and secretory activity in AtT-20 cells.

Authors:  E V Kuzhikandathil; G S Oxford
Journal:  J Neurosci       Date:  1999-03-01       Impact factor: 6.167

2.  Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells.

Authors:  M E Stockton; K Rasmussen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 3.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

4.  Dopamine activates noradrenergic receptors in the preoptic area.

Authors:  C A Cornil; J Balthazart; P Motte; L Massotte; V Seutin
Journal:  J Neurosci       Date:  2002-11-01       Impact factor: 6.167

5.  Antagonism of the effects of (+)-PD 128907 on midbrain dopamine neurones in rat brain slices by a selective D2 receptor antagonist L-741,626.

Authors:  B J Bowery; Z Razzaque; F Emms; S Patel; S Freedman; L Bristow; J Kulagowski; G R Seabrook
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

6.  Monoamine oxidase inhibition causes a long-term prolongation of the dopamine-induced responses in rat midbrain dopaminergic cells.

Authors:  N B Mercuri; M Scarponi; A Bonci; A Siniscalchi; G Bernardi
Journal:  J Neurosci       Date:  1997-04-01       Impact factor: 6.167

7.  Tyramine excites rat subthalamic neurons in vitro by a dopamine-dependent mechanism.

Authors:  Zi-Tao Zhu; Adam C Munhall; Steven W Johnson
Journal:  Neuropharmacology       Date:  2006-12-28       Impact factor: 5.250

8.  Characterization of 4-(2-hydroxyphenyl)-1-[2'-[N-(2''-pyridinyl)-p-fluorobenzamido]ethyl]piperazine (p-DMPPF) as a new potent 5-HT1A antagonist.

Authors:  C Defraiteur; A Plenevaux; J Scuvée-Moreau; N Rouchet; D Goblet; A Luxen; V Seutin
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

9.  Repeated exposure to MDMA and amphetamine: sensitization, cross-sensitization, and response to dopamine D₁- and D₂-like agonists.

Authors:  Sarah Bradbury; David Gittings; Susan Schenk
Journal:  Psychopharmacology (Berl)       Date:  2012-05-05       Impact factor: 4.530

Review 10.  Spatial and temporal scales of dopamine transmission.

Authors:  Changliang Liu; Pragya Goel; Pascal S Kaeser
Journal:  Nat Rev Neurosci       Date:  2021-04-09       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.